Want to see TMO full AI Analyst Report?
Operating Expense Breakdown
Details core costs like R&D, marketing, and admin, offering insight into how efficiently Thermo Fisher runs and where it’s prioritizing investment.R&D spending is steady, signaling continued product investment, while amortization jumped after past M&A and has been steadily rolling down—an important tailwind for margins. Offsetting that, SG&A has accelerated into early‑2026, likely reflecting Clario integration and transaction-related costs, and restructuring charges remain lumpy, obscuring underlying trends. Management’s raised guidance leans on margin expansion and productivity; the key investor watch is whether SG&A and episodic restructuring normalize so the amortization decline and operational gains translate into sustainable margin improvement despite higher leverage and FX/tariff risks.
Date | Research and Development | Amortization of Intangibles | Selling, General, and Administrative | Restructuring and Other |
|---|---|---|---|---|
Jun 30, 2026 | $364.00M | $485.00M | $1.91B | $98.00M |
Mar 31, 2026 | $336.00M | $430.00M | $2.18B | $49.00M |
Dec 31, 2025 | $357.00M | $436.00M | $1.98B | $46.00M |
Sep 30, 2025 | $346.00M | $435.00M | $1.79B | $135.00M |
Jun 30, 2025 | $352.00M | $429.00M | $1.78B | $82.00M |
Mar 31, 2025 | $342.00M | $429.00M | $1.72B | $98.00M |
Dec 31, 2024 | $374.00M | $438.00M | $1.85B | $228.00M |
Sep 30, 2024 | $346.00M | $450.00M | $1.74B | $45.00M |
Jun 30, 2024 | $339.00M | $513.00M | $1.69B | $77.00M |
Mar 31, 2024 | $331.00M | $551.00M | $1.73B | $29.00M |